Elicio released data from the New Coronary Vaccine Animal Study, which found antibody levels 265 times higher than those of the recovered.

On August 19th, Local time, Elicio Therapeutics, a new generation immunotherapy development company based in Cambridge, USA, released preclinical data on its COVID-19 candidate vaccine, ELI-005, saying that the protein sub-unit vaccine has a unique ability to stimulate T-cells to produce high-intensity responses to COVID-19, as well as effective antibody induction.
given the short antibody response of COVID-19, a long-term, effective antiviral T-cell equilibrium response can be achieved in the long-lasting protection produced after ELI-005 is given.
The core results of the study on ELI-005 in mice were as follows: 25 times the number of T-cells detected in exosomal blood (40% of cells are CD8-positive) and a first-line defense against COVID-19 in lung tissue (70% of cells are CD8-positive) and respiratory fluid; Induced to produce 265 times more coronary viral protein and antibody response than in patients with COVID-19 during recovery period; no vaccine-related respiratory disease enhancement (VAERD) risk signals, under the action of ELI-005, formed a Th1 T cell (interferon, tumor necrotic cause alpha) and Th1 antibody (IgG2bc) response spectrum; Effective antibody and T-cell responses in older mice can be maintained compared to younger mice; viral protein antigens below 10 times the dose maintain an effective immune response, suggesting that ELI-005 can reduce the supply of COVID-19 immunization in all humans.
the study showed that the ELI-005 vaccine, given every two weeks, can form a parallel response balanced across antibodies and T-cell mechanisms.
multi-functional CD4 plus CD8 plus T cells reach the lungs and secrete them into breathing fluid, forming a front-line defense against COVID-19.
VAERD risk signal did not appear in the test.
less than 10 times the dose of viral protein antigens maintains an effective immune response and therefore requires less capacity to provide ELI-005 globally.
ELI-005 consists of two parts, the first part of ELI-004 is a two-parent admission, the structure is hydrophobic protein binding lipids linked to a hydroelectric immune stimulation CpG DNA oligonucleotide (AMP-CpG).
this design enables efficient lymph node targeting, by binding AMP-CpG to tissue proteins, albumin that naturally flows into the lymph nodes and brings AMP-CpG in.
has been found that ELI-004 improves lymph node delivery by at least 10 times compared to traditional CpG and other baseline adulations, resulting in a significant increase in immune cell delivery and immune response.
the second part is the COVID-19 Spike protein bind domain (RBD), which previous studies have shown to be a target for the immune response in T-cells and coronavirus antibodies.
new crown vaccine research and development is in full swing, pharmaceutical companies and researchers around the world are scrambling to fight this global disease in the best efforts.
good data on ELI-005 in animal studies, as reported by Elicio, is eye-watering, but the long road to clinical development requires more strong evidence of the black horse's strength.
source: Lymph Node Targeting COVID-19 Vaccine Induces Up To 25-Fold More T Cells Over Benchmark Vaccines and 265-Fold GreatEr Antibody Levels Than Recovering Patients.